WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise
International Alzheimer’s prevention trial in young adults begins (Links to an external site)
Author: Ellen
Podcast: Newly approved drug may slow progression of Alzheimer’s (Links to an external site)
Lilly drug slows Alzheimer’s by 35%, bolstering treatment approach (Links to an external site)
Conquering Alzheimer’s: a look at the therapies of the future (Links to an external site)
Seeking Alzheimer’s clues from few who escape genetic fate (Links to an external site)
Lifetime Achievement Award (Links to an external site)
Focused ultrasound technique leads to release of neurodegenerative disorders biomarkers (Links to an external site)
FDA APPROVES LEQEMBI™ (LECANEMAB-IRMB) UNDER THE ACCELERATED APPROVAL PATHWAY FOR THE TREATMENT OF ALZHEIMER’S DISEASE (Links to an external site)
WashU, Eisai form drug discovery collaboration (Links to an external site)
Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)
The statement below is in response to the 14 November 2022 announcement regarding the results from the GRADUATE I and II AD studies found on Roche’s website. Roche, known as Genentech in the United States, and the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University in St. Louis have been evaluating gantenerumab in […]